Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent

Seung-Woon Rha, Pramod K. Kuchulakanti, Rajbabu Pakala, Edouard Cheneau, Jana A. Fournadjiev, Ellen Pinnow, Afework GebreEyesus, George Aggrey, Zuyue Wang, Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, Ron Waksman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions. This retrospective, observational study aimed to evaluate the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients treated with sirolimus-eluting stents (Cypher) and found that bivalirudin is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.

Original languageEnglish
Pages (from-to)1047-1050
Number of pages4
JournalAmerican Journal of Cardiology
Volume94
Issue number8
DOIs
Publication statusPublished - 2004 Oct 15
Externally publishedYes

Fingerprint

Fibrinolytic Agents
Sirolimus
Stents
Heparin
Percutaneous Coronary Intervention
Observational Studies
Blood Vessels
Retrospective Studies
Safety
bivalirudin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Rha, S-W., Kuchulakanti, P. K., Pakala, R., Cheneau, E., Fournadjiev, J. A., Pinnow, E., ... Waksman, R. (2004). Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent. American Journal of Cardiology, 94(8), 1047-1050. https://doi.org/10.1016/j.amjcard.2004.06.065

Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent. / Rha, Seung-Woon; Kuchulakanti, Pramod K.; Pakala, Rajbabu; Cheneau, Edouard; Fournadjiev, Jana A.; Pinnow, Ellen; GebreEyesus, Afework; Aggrey, George; Wang, Zuyue; Pichard, Augusto D.; Satler, Lowell F.; Kent, Kenneth M.; Lindsay, Joseph; Waksman, Ron.

In: American Journal of Cardiology, Vol. 94, No. 8, 15.10.2004, p. 1047-1050.

Research output: Contribution to journalArticle

Rha, S-W, Kuchulakanti, PK, Pakala, R, Cheneau, E, Fournadjiev, JA, Pinnow, E, GebreEyesus, A, Aggrey, G, Wang, Z, Pichard, AD, Satler, LF, Kent, KM, Lindsay, J & Waksman, R 2004, 'Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent', American Journal of Cardiology, vol. 94, no. 8, pp. 1047-1050. https://doi.org/10.1016/j.amjcard.2004.06.065
Rha, Seung-Woon ; Kuchulakanti, Pramod K. ; Pakala, Rajbabu ; Cheneau, Edouard ; Fournadjiev, Jana A. ; Pinnow, Ellen ; GebreEyesus, Afework ; Aggrey, George ; Wang, Zuyue ; Pichard, Augusto D. ; Satler, Lowell F. ; Kent, Kenneth M. ; Lindsay, Joseph ; Waksman, Ron. / Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent. In: American Journal of Cardiology. 2004 ; Vol. 94, No. 8. pp. 1047-1050.
@article{173c0e247b6149a4bf36c7fca4dc5e94,
title = "Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent",
abstract = "Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions. This retrospective, observational study aimed to evaluate the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients treated with sirolimus-eluting stents (Cypher) and found that bivalirudin is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.",
author = "Seung-Woon Rha and Kuchulakanti, {Pramod K.} and Rajbabu Pakala and Edouard Cheneau and Fournadjiev, {Jana A.} and Ellen Pinnow and Afework GebreEyesus and George Aggrey and Zuyue Wang and Pichard, {Augusto D.} and Satler, {Lowell F.} and Kent, {Kenneth M.} and Joseph Lindsay and Ron Waksman",
year = "2004",
month = "10",
day = "15",
doi = "10.1016/j.amjcard.2004.06.065",
language = "English",
volume = "94",
pages = "1047--1050",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent

AU - Rha, Seung-Woon

AU - Kuchulakanti, Pramod K.

AU - Pakala, Rajbabu

AU - Cheneau, Edouard

AU - Fournadjiev, Jana A.

AU - Pinnow, Ellen

AU - GebreEyesus, Afework

AU - Aggrey, George

AU - Wang, Zuyue

AU - Pichard, Augusto D.

AU - Satler, Lowell F.

AU - Kent, Kenneth M.

AU - Lindsay, Joseph

AU - Waksman, Ron

PY - 2004/10/15

Y1 - 2004/10/15

N2 - Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions. This retrospective, observational study aimed to evaluate the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients treated with sirolimus-eluting stents (Cypher) and found that bivalirudin is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.

AB - Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions. This retrospective, observational study aimed to evaluate the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients treated with sirolimus-eluting stents (Cypher) and found that bivalirudin is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.

UR - http://www.scopus.com/inward/record.url?scp=5044227780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5044227780&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2004.06.065

DO - 10.1016/j.amjcard.2004.06.065

M3 - Article

VL - 94

SP - 1047

EP - 1050

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 8

ER -